Patient covariates at diagnosis
| . | Training data set (n = 1955) . | Validation data set (n = 3454) . | P value . |
|---|---|---|---|
| Age, years, median (IQR) | 40 (30-52) | 42 (32- 54) | <.001 |
| Male, n (%) | 1195 (61) | 2075 (60) | .45 |
| Spleen size, cm below costal margin, median (IQR) | 3 (0-10) | 2 (0-7) | <.001 |
| WBC, ×10E+9/L, median (IQR) | 122 (47-235) | 123 (51-225) | .59 |
| Hemoglobin, ×10E+9/L, median (IQR) | 115 (97-132) | 111 (94-127) | <.001 |
| Platelets, ×10E+9/L, median (IQR) | 410 (270-635) | 412 (263-625) | .99 |
| Blood blasts, %, median (IQR) | 1 (0-3) | 1 (0-2) | <.001 |
| Blood basophils, %, median (IQR) | 5 (2-8) | 4 (2-7) | <.001 |
| Blood eosinophils, %, median (IQR) | 2 (1-4) | 2 (1-4) | .73 |
| Sokal risk, n (%) | <.001 | ||
| Low | 819 (42) | 1526 (44) | |
| Intermediate | 555 (28) | 1157 (33) | |
| High | 394 (20) | 543 (16) | |
| Unknown | 187 (10) | 228 (7) | |
| ELTS risk, n (%) | <.001 | ||
| Low | 1115 (57) | 2207 (64) | |
| Intermediate | 471 (24) | 795 (23) | |
| High | 182 (9) | 224 (6) | |
| Unknown | 187 (10) | 228 (7) | |
| Ph+ACAs, n (%) | 68 (3) | 118 (3) | .90 |
| High-risk ACAs, n (%) | 41 (2) | 51 (1) | .09 |
| Comorbidity(ies), n (%) | 700 (36) | 694 (20) | <.001 |
| Initial TKI therapy, n (%) | <.001 | ||
| Imatinib | 1539 (79) | 2386 (69) | |
| 2G TKI | 416 (21) | 1068 (31) | |
| Nilotinib | 280 (14) | 620 (18) | |
| Dasatinib | 72 (4) | 154 (4) | |
| Flumatinib | 64 (3) | 294 (9) | |
| Follow-up∗, mo, median (IQR) | 56 (30-91) | 45 (26-76) | <.001 |
| . | Training data set (n = 1955) . | Validation data set (n = 3454) . | P value . |
|---|---|---|---|
| Age, years, median (IQR) | 40 (30-52) | 42 (32- 54) | <.001 |
| Male, n (%) | 1195 (61) | 2075 (60) | .45 |
| Spleen size, cm below costal margin, median (IQR) | 3 (0-10) | 2 (0-7) | <.001 |
| WBC, ×10E+9/L, median (IQR) | 122 (47-235) | 123 (51-225) | .59 |
| Hemoglobin, ×10E+9/L, median (IQR) | 115 (97-132) | 111 (94-127) | <.001 |
| Platelets, ×10E+9/L, median (IQR) | 410 (270-635) | 412 (263-625) | .99 |
| Blood blasts, %, median (IQR) | 1 (0-3) | 1 (0-2) | <.001 |
| Blood basophils, %, median (IQR) | 5 (2-8) | 4 (2-7) | <.001 |
| Blood eosinophils, %, median (IQR) | 2 (1-4) | 2 (1-4) | .73 |
| Sokal risk, n (%) | <.001 | ||
| Low | 819 (42) | 1526 (44) | |
| Intermediate | 555 (28) | 1157 (33) | |
| High | 394 (20) | 543 (16) | |
| Unknown | 187 (10) | 228 (7) | |
| ELTS risk, n (%) | <.001 | ||
| Low | 1115 (57) | 2207 (64) | |
| Intermediate | 471 (24) | 795 (23) | |
| High | 182 (9) | 224 (6) | |
| Unknown | 187 (10) | 228 (7) | |
| Ph+ACAs, n (%) | 68 (3) | 118 (3) | .90 |
| High-risk ACAs, n (%) | 41 (2) | 51 (1) | .09 |
| Comorbidity(ies), n (%) | 700 (36) | 694 (20) | <.001 |
| Initial TKI therapy, n (%) | <.001 | ||
| Imatinib | 1539 (79) | 2386 (69) | |
| 2G TKI | 416 (21) | 1068 (31) | |
| Nilotinib | 280 (14) | 620 (18) | |
| Dasatinib | 72 (4) | 154 (4) | |
| Flumatinib | 64 (3) | 294 (9) | |
| Follow-up∗, mo, median (IQR) | 56 (30-91) | 45 (26-76) | <.001 |
WBC, white blood cell.
Censored at a transplant, death, or the last follow-up.